Investors

Global Links


Management Team

Investors

Press Releases

DateSubject
November 20, 2007 Cerus Announces Spin-off of Immunotherapy Business
November 2, 2007 Cerus Announces Webcast of Corporate Presentation at the JMP Securities Healthcare Focus Conference
October 30, 2007 Cerus Corporation Announces Third Quarter Financial Results
October 25, 2007 Cerus Elects Gail Schulze to Board of Directors
October 16, 2007 Cerus Corporation to Release Third Quarter Financial Results on Tuesday, October 30, 2007
September 14, 2007 Cerus Announces Webcast of Corporate Presentation at the 2007 UBS Global Life Sciences Conference
July 31, 2007 Cerus Corporation Announces Second Quarter Financial Results
July 23, 2007 Grifols S.A. and Cerus Corporation Agree to Commercialize the INTERCEPT Blood System in Spain and Portugal
June 26, 2007 Cerus Corporation to Hold Conference Call to Discuss Corporate Update
June 26, 2007 Cerus Announces Agreement to Supply the INTERCEPT Blood System for Platelets to French National Blood Service
May 16, 2007 Cerus Announces Webcast of Corporate Presentation at the 6th Annual JMP Securities Research Conference
May 15, 2007 INTERCEPT Plasma Gains Registration in French Official Journal
May 1, 2007 Cerus Corporation Announces First Quarter Financial Results
April 26, 2007 Cerus to Explore Strategic Alternatives for Its Immunotherapy Programs
April 24, 2007 Cerus Corporation to Release First Quarter Financial Results on Tuesday, May 1, 2007
March 6, 2007 Cerus Announces Webcast of Corporate Presentation at the Cowen & Company 27th Annual Healthcare Conference
March 5, 2007 Cerus Corporation Awarded Grants for Its Listeria-Based Vaccine Platforms
February 27, 2007 Cerus Corporation Announces Fourth Quarter and Year-End Financial Results
February 8, 2007 Cerus Corporation to Release Fourth Quarter and Year End 2006 Financial Results on Thursday, February 22, 2007
January 29, 2007 Cerus' INTERCEPT Blood System Receives First Approval in Germany
January 17, 2007 Cerus Announces French Regulatory Approval of the INTERCEPT Blood System for Plasma